REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH): Form 8-K filed 2026-11-13
- Accepted by EDGAR
- 2026-11-12 20:30 ET
- Event date
- 2026-11-12
- Accession no.
- 0001437749-26-036647
- Original filing
- SEC EDGAR filing index
AI summary of the filing text. It can contain mistakes; the original filing is authoritative.
Reviva reports third quarter results and updates brilaroxazine development plans
Reviva reported a net loss of approximately $2.3 million for the quarter ended September 30, 2026, compared with approximately $4.0 million a year earlier. It expects FDA feedback on its new brilaroxazine formulation in Q4 2026 and RECOVER-2 patient enrollment in 1H 2027, subject to receipt of additional financing.
- Net loss was approximately $2.3 million, or $0.17 per share, versus approximately $4.0 million, or $1.09 per share, a year earlier.
- Cash and cash equivalents totaled approximately $17.5 million as of September 30, 2026.
- FDA feedback on the new brilaroxazine formulation is expected in Q4 2026.
- RECOVER-2 patient enrollment is expected to begin in 1H 2027, subject to receipt of additional financing.
earningsproductregulatory
Items reported
- Item 2.02: Results of Operations and Financial Condition
The company publicly announced results of operations or financial condition for a completed period, most often a quarterly earnings release. The release itself is usually attached as Exhibit 99.1. Information under Item 2.02 is generally "furnished" rather than "filed". - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | FORM 8-K | rvph20261106_8k.htm |
| EX-99.1 | EXHIBIT 99.1 | ex_1042036.htm |
The summary above was generated by AI from the filing text and checked automatically against it. Read the original documents on SEC EDGAR. How to read an 8-K.